Get up to date on optimal management of follicular lymphoma with multidisciplinary expert perspectives on selecting frontline therapy, sequencing treatments for relapsed or refractory disease, and utilizing rituximab biosimilars and alternative formulations, along with promising investigational agents.
How will you incorporate tazemetostat, an EZH2 inhibitor, into your clinical practice for patients with relapsed/refractory follicular lymphoma? Here are my thoughts.
Read this expert commentary for an overview of our updated treatment decision support tool for follicular lymphoma that provides treatment recommendations from 5 lymphoma experts for your patients with newly diagnosed and relapsed/refractory disease.
Download this PDF clinical resource to help optimize care of your patients with follicular lymphoma, including a treatment algorithm for newly diagnosed and relapsed/refractory disease and a toxicity management table.
Download this ExpressPoints slideset for a quick summary of the latest clinical data informing optimal management of newly diagnosed and relapsed/refractory follicular lymphoma.
Download this slideset to review the latest clinical data informing optimal management strategies for both newly diagnosed and relapsed/refractory follicular lymphoma, including a peek at novel therapies under investigation.
Use this Interactive Decision Support Tool to compare your choice of therapy for patients with newly diagnosed or relapsed/refractory follicular lymphoma with those of 5 renowned lymphoma experts.